- Funding Received
- $4 Million in 4 Rounds from 1 Investor
- Most Recent Funding
- $2 Million Series A on February 21, 2014
- Kerecis is a developer of patent-pending MariGen™, an omega3 fish-skin acellular dermal matrix transplantation technology.
- Baldur Tumi Baldursson, Gudmundur F. Sigurjonsson, J. Ernest Kenney, Hilmar Kjartansson (M.D.)
- Medical Devices
Kerecis is developing the MariGen™ Omega3 acellular dermal matrix technology for use in products to treat chronic wounds, for hernia repair, breast reconstruction and abdominal wall reconstruction. Our patent pending acellular fish skin derived material improves upon current human and porcine technologies through improved economics and clinical performance, reduced disease transfer risk and absence of cultural constraints on usage.
Current Team (6)Update
Funding Rounds (4) - $4MUpdate
Reykjavik, Iceland Office